Supplementary Table 1. Baseline characteristics and prevalence of CVD according to 5 subcohorts

Characteristics	Subcohort					P value
	DN	HTN	GN	PKD	Unclassified	
Participants	519	409	810	364	136	
Age, yr	59.3 ± 9.4	59.6 ± 10.8	49.8 ± 12.1	46.9 ± 10.6	55.4 ± 13.0	< 0.001
Female	162 (31.2)	114 (27.9)	359 (44.3)	180 (49.5)	54 (39.7)	< 0.001
Hypertension	513 (99.8)	409 (100.0)	785 (96.9)	314 (86.3)	131 (96.3)	< 0.001
DM	519 (100.0)	72 (17.6)	70 (8.6)	12 (3.3)	82 (60.3)	< 0.001
Current smoker	84 (16.4)	71 (17.4)	115 (14.2)	55 (15.1)	24 (17.6)	< 0.001
Height, cm	164.5 ± 8.2	164.8 ± 8.2	164.3 ± 8.2	166.1 ± 9.1	163.2 ± 8.1	0.003
Weight, kg	68.4 ± 11.4	68.4 ± 12.3	65.6 ± 11.7	65.2 ± 12.0	67.5 ± 12.1	< 0.001
BMI, kg/m^2	25.2 ± 3.2	25.1 ± 3.5	24.2 ± 3.3	23.5 ± 3.0	25.3 ± 3.9	< 0.001
Waist-to-hip ratio	0.93 ± 0.06	0.91 ± 0.06	0.88 ± 0.07	0.88 ± 0.06	0.92 ± 0.06	< 0.001
SBP, mmHg	134.3 ± 18.5	127.8 ± 15.9	123.4 ± 14.2	128.3 ± 13.3	130.3 ± 19.8	< 0.001
DBP, mmHg	75.7 ± 11.7	77.7 ± 11.5	75.6 ± 10.1	81.0 ± 10.4	76.9 ± 13.2	< 0.001
CKD stages						< 0.001
Stage 1	13 (2.5)	11 (2.7)	131 (16.2)	94 (25.8)	16 (11.8)	
Stage 2	44 (8.5)	48 (11.7)	180 (22.2)	118 (32.4)	29 (21.3)	
Stage 3a	72 (13.9)	95 (23.2)	163 (20.1)	52 (14.3)	21 (15.4)	
Stage 3b	131 (25.2)	112 (27.4)	158 (19.5)	45 (12.4)	38 (27.9)	
Stage 4	198 (38.2)	118 (28.9)	138 (17.0)	42 (11.5)	26 (19.1)	
Stage 5	61 (11.8)	25 (6.1)	40 (4.9)	13 (3.6)	6 (4.4)	
CVD						
Any CVD	130 (25.0)	88 (21.5)	56 (6.9)	25 (6.9)	22 (16.2)	< 0.001
Coronary disease	60 (11.6)	32 (7.8)	14 (1.7)	2 (0.5)	10 (7.4)	< 0.001
MI	18 (3.5)	9 (2.2)	6 (0.7)	1 (0.3)	2 (1.5)	< 0.001
Stroke	51 (9.8)	38 (9.3)	19 (2.3)	21 (5.8)	6 (4.4)	< 0.001
PAD	32 (6.2)	20 (4.9)	13 (1.6)	1 (0.3)	12 (8.8)	< 0.001
Arrhythmia	16 (3.1)	18 (4.4)	18 (2.2)	2 (0.5)	2 (1.5)	0.040
Urine ACR, mg/g						< 0.001
A1 (< 30)	21 (4.3)	101 (26.1)	44 (5.8)	151 (42.9)	18 (13.2)	
A2 (30–300)	101 (20.5)	126 (32.6)	214 (28.4)	169 (48.0)	41 (30.1)	
A3 (≥ 300)	370 (75.2)	160 (41.3)	496 (65.8)	32 (9.1)	77 (56.6)	
Creatinine, mg/dL	2.4 ± 1.3	2.0 ± 1.2	1.6 ± 1.0	1.3 ± 0.9	1.7 ± 0.9	< 0.001
Cystatin C, mg/L	2.3 ± 1.0	1.9 ± 0.9	1.6 ± 0.9	1.3 ± 0.7	1.5 ± 0.7	< 0.001
eGFR, mL/min/1.73 m^2	35.2 ± 20.6	40.8 ± 21.2	56.9 ± 31.8	68.1 ± 33.3	52.3 ± 30.1	< 0.001
Total cholesterol, mg/dL	178.9 ± 33.5	167.3 ± 43.7	169.3 ± 35.6	178.4 ± 39.0	176.7 ± 42.6	< 0.001
LDL cholesterol, mg/dL	91.0 ± 33.9	94.1 ± 30.8	100.1 ± 32.4	101.8 ± 27.1	96.2 ± 31.0	< 0.001
HDL cholesterol, mg/dL	43.6 ± 14.1	46.7 ± 14.1	51.5 ± 15.8	54.6 ± 14.0	51.0 ± 17.0	< 0.001
Hemoglobin, g/dL	11.7 ± 1.8	13.3 ± 2.0	13.2 ± 1.9	13.2 ± 1.8	12.9 ± 2.2	< 0.001
Albumin, g/dL	4.0 ± 0.5	4.3 ± 0.3	4.1 ± 0.4	4.4 ± 0.3	4.2 ± 0.5	< 0.001
Phosphorus, mg/dL	4.0 ± 0.8	3.6 ± 0.6	3.6 ± 0.6	3.6 ± 0.6	3.8 ± 0.6	< 0.001
Troponin T, ng/mL	0.029 ± 0.031	0.015 ± 0.015	0.010 ± 0.009	0.007 ± 0.004	0.030 ± 0.042	< 0.001
hsCRP, mg/L*	0.7 (0.1–52.7)	0.8 (0–67.0)	0.5 (0–68.0)	0.4 (0–35.3)	1.1 (1.0–2.0)	< 0.001
Intact PTH, pg/mL*	63.4 (14.2–1,078.0)	52.3 (19.1–660.3)	44.4 (7.0–552.3)	56.3 (21.8–414.9)	42.7 (20.0–65.0)	< 0.001
ARB	419 (80.7)	318 (77.8)	669 (82.6)	270 (74.2)	109 (80.1)	0.025
ACEi	63 (12.1)	33 (8.1)	123 (15.2)	18 (4.9)	12 (8.8)	< 0.001
CCB	295 (56.8)	218 (53.3)	216 (26.7)	120 (33.0)	57 (41.9)	< 0.001
Statin	329 (63.4)	234 (57.2)	419 (51.7)	98 (26.9)	72 (52.9)	< 0.001

Values are presented as number (%) or mean±standard deviation.
CVD=cardiovascular disease, CKD=chronic kidney disease, DN=diabetic nephropathy, HTN=hypertensive nephropathy, GN=glomerulonephritis, PKD=polycystic kidney disease, BMI=body mass index, DM=diabetes mellitus, SBP=systolic blood pressure, DBP=diastolic blood pressure, MI=myocardial infarction, PAD=peripheral arterial disease, ACR=albumin-to-creatinine ratio, eGFR=estimated glomerular filtration rate, LDL=low-density lipoprotein, HDL=high-density lipoprotein, hsCRP=high-sensitive C-reactive protein, PTH=parathyroid hormone, ARB=angiotensin receptor blocker, ACEi=angiotensin converting enzyme inhibitor, CCB=calcium channel blocker.
*Data are expressed as median and ranges (minimum to maximum).